Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

Josef S Smolen; Jonathan Kay; Robert B M Landewé; Eric L Matteson; Norman Gaylis; Jurgen Wollenhaupt; Frederick T Murphy; Yiying Zhou; Elizabeth C Hsia; Mittie K Doyle

doi:10.1136/annrheumdis-2011-200956

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2011-200956 ◽

2012 ◽

Vol 71 (10) ◽

pp. 1671-1679 ◽

Cited By ~ 38

Author(s):

Josef S Smolen ◽

Jonathan Kay ◽

Robert B M Landewé ◽

Eric L Matteson ◽

Norman Gaylis ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Previous Experience ◽

Double Blind ◽

Double Blind Placebo ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

The Lancet ◽

10.1016/s0140-6736(17)31429-0 ◽

2017 ◽

Vol 389 (10086) ◽

pp. 2317-2327 ◽

Cited By ~ 162

Author(s):

Peter Nash ◽

Bruce Kirkham ◽

Masato Okada ◽

Proton Rahman ◽

Benard Combe ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

The Lancet ◽

10.1016/s0140-6736(12)61424-x ◽

2013 ◽

Vol 381 (9865) ◽

pp. 451-460 ◽

Cited By ~ 393

Author(s):

Gerd R Burmester ◽

Ricardo Blanco ◽

Christina Charles-Schoeman ◽

Jürgen Wollenhaupt ◽

Cristiano Zerbini ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

SAT0115 Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis Who have had an Inadequate Response to Tumour Necrosis Factor Inhibitors - A Network Meta-Analysis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1841 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A619.3-A620 ◽

Cited By ~ 1

Author(s):

M. C. Vieira ◽

G. Wallenstein ◽

J. Bradley ◽

D. Gruben ◽

T. Koncz ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Meta Analysis ◽

Inadequate Response ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

THU0078 Effects of Concomitant Methotrexate on the Long-Term Outcome of Knee Joint Destruction in Patients with Rheumatoid Arthritis Treated with Tumour Necrosis Factor Inhibitors

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1337 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 220.1-220

Author(s):

S. Asai ◽

N. Takahashi ◽

K. Funahashi ◽

Y. Yoshioka ◽

T. Takemoto ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Knee Joint ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Joint Destruction ◽

Term Outcome ◽

Long Term Outcome ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

THU0136 Long Term Outcomes of Stopping Tumour Necrosis Factor Inhibitors (TNFI) in Patients with Established Rheumatoid Arthritis (RA) Who are in Sustained Remission: Is it Worth the Risk?

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.664 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A208.3-A209 ◽

Cited By ~ 4

Author(s):

C. Rakieh ◽

B. Saleem ◽

K. Takase ◽

J. L. Nam ◽

H. Keen ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Sustained Remission ◽

Established Rheumatoid Arthritis ◽

Long Term Outcomes ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid arthritis

Rheumatology International ◽

10.1007/s00296-009-0935-2 ◽

2009 ◽

Vol 30 (2) ◽

pp. 193-198 ◽

Cited By ~ 27

Author(s):

A. Ferrante ◽

A. R. Giardina ◽

F. Ciccia ◽

G. Parrinello ◽

G. Licata ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Intima Media Thickness ◽

Carotid Intima Media Thickness ◽

Media Thickness ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-015-0037-9 ◽

2015 ◽

Vol 13 (1) ◽

Cited By ~ 2

Author(s):

Álvaro Hidalgo-Vega ◽

Renata Villoro ◽

Juan Antonio Blasco ◽

Pablo Talavera ◽

Belén Ferro ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Certolizumab Pegol ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

The Lancet ◽

10.1016/s0140-6736(09)60506-7 ◽

2009 ◽

Vol 374 (9685) ◽

pp. 210-221 ◽

Cited By ~ 338

Author(s):

Josef S Smolen ◽

Jonathan Kay ◽

Mittie K Doyle ◽

Robert Landewé ◽

Eric L Matteson ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Tumour Necrosis Factor Α ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

078 Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study

Rheumatology ◽

10.1093/rheumatology/kew144.005 ◽

2016 ◽

Cited By ~ 1

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Inadequate Response ◽

Efficacy And Safety ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1104777.560749 ◽

2008 ◽

Author(s):

Geoff Littlejohn

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Population Based ◽

Population Based Study ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text